DMK Pharmaceuticals Corporation
DMK Pharmaceuticals Corporation (DMKPQ) Revenue
Annual & quarterly revenue history · segment & region breakdown
DMKPQ · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsDMK Pharmaceuticals Corporation trailing twelve-month (TTM) revenue is $0.00B, an increase of 115.34% year-over-year from $0.00B in FY2022.
Revenue trend
2022 – 2016 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2022-12-31 | $0.00B | +$0.00B | +115.34% |
| 2021-12-31 | $0.00B | -$0.00B | -20.45% |
| 2020-12-31 | $0.00B | -$0.02B | -87.44% |
| 2019-12-31 | $0.02B | +$0.01B | +46.58% |
| 2018-12-31 | $0.02B | +$0.00B | +15.40% |
| 2017-12-31 | $0.01B | +$0.01B | +101.94% |
| 2016-12-31 | $0.01B | — | — |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income DMK Pharmaceuticals Corporation receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
DMK Pharmaceuticals Corporation reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from DMK Pharmaceuticals Corporation's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
DMKPQ revenue · 4 questionsDMKPQ's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 115.34% year-over-year from $0.00B in FY2022.
▸ Source: FMP · DMK Pharmaceuticals Corporation SEC filings · GAAP · DMK Pharmaceuticals Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026